scholarly journals Condilomas Anogenitais numa Consulta de Doenças Sexualmente Transmissíveis: Centro de Saúde da Lapa - Lisboa, 2008 a 2014

2016 ◽  
Vol 29 (2) ◽  
pp. 101 ◽  
Author(s):  
Ana Gameiro ◽  
João Alves ◽  
Irene Santo ◽  
Jacinta Azevedo
Keyword(s):  
Human Papillomavirus ◽  
Vaccination Program ◽  
Quadrivalent Vaccine ◽  
First Episode ◽  
Anogenital Warts ◽  
Human Papillomavirus Vaccination ◽  
Transmitted Infection ◽  
Papillomavirus Infection ◽  
Number Of Sexual Partners ◽  
Old Females

<p><strong>Introduction:</strong> Human papillomavirus infection is the most common sexual transmitted infection in the world, being associated with different diseases, namely anogenital warts, recurrent respiratory papillomatosis and anal, cervical, and oropharyngeal cancers. Among sexually active people, approximately 1% has anogenital warts, 90% of cases resulting from genotypes 6 and 11.<br /><strong>Material and Methods:</strong> Patients diagnosed with first episode of anogenital warts from 2008 to 2014 in Lisbon’s major venereology clinic were identified, and characterized according to sex, sexual orientation, age, warts location, and number of sexual partners. <br /><strong>Results:</strong> We observed a statistically significant decrease in first anogenital warts diagnosis among &lt; 19 year old females (r = -0.848;<br />p = 0.016) and a non-statistically significant decrease among &lt; 19 – year-old males and among 20 – 24 year old females.<br /><strong>Discussion:</strong> In October 2008, the quadrivalent vaccine (genotypes 6, 11, 16, 18) was introduced in the Portuguese national vaccination program, targeting 13-year-old females, with a catch-up for 17 year old females. In the women´s group, decrease in first anogenital warts diagnosis is probably related to human papillomavirus vaccination before onset of sexual activity.<br /><strong>Conclusion:</strong> This study reinforces the importance of national human papillomavirus vaccination program.</p>

Early Evidence of the Effectiveness of the Human Papillomavirus Vaccination Program Against Anogenital Warts in Manitoba, Canada

2018 ◽  
Vol 45 (4) ◽  
pp. 254-259 ◽  
Author(s):  
Karla Willows ◽  
Songul Bozat-Emre ◽  
Christiaan H. Righolt ◽  
Erich V. Kliewer ◽  
Salaheddin M. Mahmud
Keyword(s):  
Human Papillomavirus ◽  
Vaccination Program ◽  
Anogenital Warts ◽  
Human Papillomavirus Vaccination ◽  
Early Evidence

scholarly journals Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14–26 year old females in the U.S.

Vaccine ◽  
2018 ◽  
Vol 36 (50) ◽  
pp. 7682-7688 ◽  
Author(s):  
Jacqueline Hirth ◽  
Christine J. McGrath ◽  
Yong-Fang Kuo ◽  
Richard E. Rupp ◽  
Jonathan M. Starkey ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Ethnic Disparities ◽  
Human Papillomavirus Vaccination ◽  
Vaccine Type ◽  
Racial Ethnic ◽  
Old Females ◽  
The U.S

The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada

2017 ◽  
Vol 90 (3) ◽  
pp. 592-598 ◽  
Author(s):  
Marc Steben ◽  
Najwa Ouhoummane ◽  
Caroline Rodier ◽  
Liliya Sinyavskaya ◽  
Paul Brassard
Keyword(s):  
Human Papillomavirus ◽  
Anogenital Warts ◽  
Human Papillomavirus Vaccination

Papillomaviruses and polyomaviruses

2020 ◽  
pp. 877-885
Author(s):  
Raphael P. Viscidi ◽  
Chen Sabrina Tan ◽  
Carole Fakhry
Keyword(s):  
Human Papillomavirus ◽  
Sexually Transmitted Infection ◽  
Sexual Contact ◽  
Prophylactic Vaccine ◽  
Basal Cells ◽  
Anogenital Warts ◽  
Transmitted Infection ◽  
Sexually Transmitted ◽  
Surgical Methods ◽  
Flat Lesions

There are nearly 200 human papillomavirus types that infect epithelia of skin and mucous membranes. They infect only humans, and cause conditions including the following: skin warts and verrucas, which are caused by types 1 and 2; infection initiated when, after minor skin abrasions, for example, the basal cells of the epithelium come in contact with infectious virus; anogenital warts, which are caused by types 6 and 11; transmitted by direct sexual contact, these are the most common sexually transmitted infection; present clinically as multiple exophytic lesions or as subclinical flat lesions. They can be treated topically with podophyllin or imiquimod, or by ablative surgical methods. Recurrences are common. A highly efficacious prophylactic vaccine is available.

scholarly journals School-based human papillomavirus vaccination program for increasing vaccine uptake in an underserved area in Texas

2019 ◽  
Vol 8 ◽  
pp. 100189 ◽  
Author(s):  
Sapna Kaul ◽  
Thuy Quynh N. Do ◽  
Enshuo Hsu ◽  
Kathleen M. Schmeler ◽  
Jane R. Montealegre ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Vaccine Uptake ◽  
Vaccination Program ◽  
Underserved Area ◽  
Human Papillomavirus Vaccination ◽  
School Based

scholarly journals A human papillomavirus vaccination program for low-income postpartum women

2016 ◽  
Vol 215 (3) ◽  
pp. 318.e1-318.e9 ◽  
Author(s):  
Abbey B. Berenson ◽  
Mahbubur Rahman ◽  
Jacqueline M. Hirth ◽  
Richard E. Rupp ◽  
Kwabena O. Sarpong
Keyword(s):  
Human Papillomavirus ◽  
Low Income ◽  
Vaccination Program ◽  
Postpartum Women ◽  
Human Papillomavirus Vaccination

scholarly journals Cost-effectiveness of a bivalent human papillomavirus vaccination program in Japan

Sexual Health ◽  
2015 ◽  
Vol 12 (6) ◽  
pp. 520 ◽  
Author(s):  
Luke B. Connelly ◽  
Ha N. D. Le
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Cost Effectiveness ◽  
Screening Program ◽  
Vaccine Coverage ◽  
Precancerous Lesions ◽  
Hpv Vaccination ◽  
Vaccination Program ◽  
Human Papillomavirus Vaccination ◽  
The Cost

Background Human papillomavirus (HPV) vaccines and their widespread adoption have the potential to relieve a large part of the burden of cervical cancer morbidity and mortality, particularly in countries that have low screening rates or, like Japan, lack a cohesive universal screening program. An economic evaluation was conducted to assess the cost-effectiveness of introducing a bivalent HPV vaccination program in Japan from a healthcare perspective. Methods: A Markov model of the natural history of HPV infection that incorporates both vaccination and screening was developed for Japan. The modelled intervention, a bivalent HPV vaccine with a 100% lifetime vaccine efficacy and 80% vaccine coverage, given to a cohort of 12-year-old Japanese girls in conjunction with the current screening program, was compared with screening alone in terms of costs and effectiveness. A discount rate of 5% was applied to both costs and utilities where relevant. Results: Vaccination alongside screening compared with screening alone is associated with an incremental cost-effectiveness ratio (ICER) of US$20 315 per quality-adjusted-life-year gained if 80% coverage is assumed. The ICER at 5% coverage with the vaccine plus screening, compared with screening alone, is US$1158. Conclusion: The cost-effectiveness results suggest that the addition of a HPV vaccination program to Japan’s cervical cancer screening program is highly likely to prove a cost-effective way to reduce the burden of cervical cancer, precancerous lesions and HPV16/18-related diseases.

Sign in / Sign up

Export Citation Format

Share Document